Susceptibilities of clinical Clostridium difficile isolates to antimicrobials: a systematic review and meta-analysis of studies since 1970

Clinical Microbiology and Infection

Volumn 24, Issue 2, 2018, Pages 110-117

  Khanafer, N ^a,b   Daneman, N ^c   Greene, T ^d   Simor, A ^c   Vanhems, P ^a,b   Samore, M ^d,e   Brown, K A ^c,d,e,f  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF UTAH   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

Antibiotic; Clostridium difficile; Minimum inhibitory concentration; Strain; Susceptibility

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; FIDAXOMICIN; GLYCOPEPTIDE; IMIDAZOLE DERIVATIVE; LINCOSAMIDE; MACROLIDE; METRONIDAZOLE; PENICILLIN DERIVATIVE; RIFAMYCIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; META ANALYSIS; MIC50; MIC90; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ANTIBIOTIC RESISTANCE; DRUG EFFECT; HUMAN; PSEUDOMEMBRANOUS COLITIS;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS;

EID: 85030460977     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2017.07.012     Document Type: Review

References (40)

1. Brown, K.A., Khanafer, N., Daneman, N., Fisman, D.N., Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 57:5 (2013), 2326–2332.
2. Slimings, C., Riley, T.V., Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 69:4 (2014), 881–891.
3. Stevens, V., Dumyati, G., Fine, L.S., Fisher, S.G., van Wijngaarden, E., Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 53:1 (2011), 42–48.
4. Owens, R.C. Jr., Donskey, C.J., Gaynes, R.P., Loo, V.G., Muto, C.A., Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46:Suppl. 1 (2008), S19–S31.
5. Noren, T., Alriksson, I., Akerlund, T., Burman, L.G., Unemo, M., In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect 16:8 (2010), 1104–1110.
6. Bourgault, A.M., Lamothe, F., Loo, V.G., Poirier, L., Group CDAD-CSI Study Group. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada. Antimicrob Agents Chemother 50:10 (2006), 3473–3475.
7. Pepin, J., Saheb, N., Coulombe, M.A., Alary, M.E., Corriveau, M.P., Authier, S., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41:9 (2005), 1254–1260.
8. Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:15 (2000), 2008–2012.
9. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:4 (2009), 264–269.
10. O'Rourke, K., Detsky, A.S., Meta-analysis in medical research: strong encouragement for higher quality in individual research efforts. J Clin Epidemiol 42 (1989), 1021–1024.
11. Turnidge, J., Paterson, D.L., Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20:3 (2007), 391–408.
12. Higgins, P.G., Coleman, K., Amyes, S.G., Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro. J Antimicrob Chemother 45:Suppl. 1 (2000), 71–77.
13. Austin, P.C., Merlo, J., Intermediate and advanced topics in multilevel logistic regression analysis. Stat Med 36:20 (2017), 3257–3277.
14. Bolker, B.M., Brooks, M.E., Clark, C.J., Geange, S.W., Poulsen, J.R., Stevens, M.H., et al. Generalized linear mixed models: a practical guide for ecology and evolution. Trends Ecol Evol 24:3 (2009), 127–135.
15. Baron, S., Medical microbiology. 4th ed., 1996, University of Texas, Medical Branch at Galveston, Texas: Galveston, Tex.
16. Pirs, T., Avbersek, J., Zdovc, I., Krt, B., Andlovic, A., Lejko-Zupanc, T., et al. Antimicrobial susceptibility of animal and human isolates of Clostridium difficile by broth microdilution. J Med Microbiol 62:Pt 9 (2013), 1478–1485.
17. John, R., Brazier, J.S., Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 61:1 (2005), 11–14.
18. Foye, W.O., Lemke, T.L., Williams, D.A., Foye's principles of medicinal chemistry. 2013, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
19. Karlowsky, J.A., Zhanel, G.G., Hammond, G.W., Rubinstein, E., Wylie, J., Du, T., et al. Multidrug-resistant North American pulsotype 2 Clostridium difficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006-2007. J Med Microbiol 61:Pt 5 (2012), 693–700.
20. Samore, M.H., Venkataraman, L., DeGirolami, P.C., Merrigan, M.M., Johnson, S., Gerding, D.N., et al. Genotypic and phenotypic analysis of Clostridium difficile correlated with previous antibiotic exposure. Microb Drug Resist 12:1 (2006), 23–28.
21. Versporten, A., Coenen, S., Adriaenssens, N., Muller, A., Minalu, G., Faes, C., et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe (1997-2009). J Antimicrob Chemother 66:Suppl. 6 (2011), vi13–vi23.
22. Currie, C.J., Berni, E., Jenkins-Jones, S., Poole, C.D., Ouwens, M., Driessen, S., et al. Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis. BMJ, 349, 2014, g5493.
23. Van Boeckel, T.P., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B.T., Levin, S.A., et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 14:8 (2014), 742–750.
24. Roberts, S., Heffernan, H., Al Anbuky, N., Pope, C., Paviour, S., Camp, T., et al. Molecular epidemiology and susceptibility profiles of Clostridium difficile in New Zealand, 2009. New Zealand Med J 124:1332 (2011), 45–51.
25. Deshpande, A., Pant, C., Jain, A., Fraser, T.G., Rolston, D.D., Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin 24:2 (2008), 329–333.
26. Weber, I., Riera, E., Deniz, C., Perez, J.L., Oliver, A., Mena, A., Molecular epidemiology and resistance profiles of Clostridium difficile in a tertiary care hospital in Spain. Int J Med Microbiol 303:3 (2013), 128–133.
27. Novak, A., Spigaglia, P., Barbanti, F., Goic-Barisic, I., Tonkic, M., First clinical and microbiological characterization of Clostridium difficile infection in a Croatian University Hospital. Anaerobe 30 (2014), 18–23.
28. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Available at: www.eucast.org.
29. Nelson, R.L., Kelsey, P., Leeman, H., Meardon, N., Patel, H., Paul, K., et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev(9), 2011, CD004610.
30. Snydman, D.R., Jacobus, N.V., McDermott, L.A., Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother 56:6 (2012), 3448–3452.
31. Baines, S.D., O'Connor, R., Freeman, J., Fawley, W.N., Harmanus, C., Mastrantonio, P., et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 62:5 (2008), 1046–1052.
32. Dzink, J., Bartlett, J.G., In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother 17:4 (1980), 695–698.
33. Shuttleworth, R., Taylor, M., Jones, D.M., Antimicrobial susceptibilities of Clostridium difficile. J Clin Pathol 33:10 (1980), 1002–1005.
34. Kim, J., Kang, J.O., Pai, H., Choi, T.Y., Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea. Int J Antimicrob Agents 40:1 (2012), 24–29.
35. Nakamura, S., Nakashio, S., Mikawa, M., Yamakawa, K., Okumura, S., Nishida, S., Antimicrobial susceptibility of Clostridium difficile from different sources. Microbiol Immunol 26:1 (1982), 25–30.
36. Tang-Feldman, Y.J., Henderson, J.P., Ackermann, G., Feldman, S.S., Bedley, M., Silva, J. Jr., et al. Prevalence of the ermB gene in Clostridium difficile strains isolated at a university teaching hospital from 1987 through 1998. Clin Infect Dis 40:10 (2005), 1537–1540.
37. Wust, J., Hardegger, U., Studies on the resistance of Clostridium difficile to antimicrobial agents. Zentralbl Bakteriol Mikrobiol Hyg A 267:3 (1988), 383–394.
38. Huang, H., Weintraub, A., Fang, H., Wu, S., Zhang, Y., Nord, C.E., Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Anaerobe 16:6 (2010), 633–635.
39. Spigaglia, P., Barbanti, F., Mastrantonio, P., European Study Group on Clostridium difficile. Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 66:10 (2011), 2227–2234.
40. Herpers, B.L., Vlaminckx, B., Burkhardt, O., Blom, H., Biemond-Moeniralam, H.S., Hornef, M., et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 48:12 (2009), 1732–1735.